Now Playing
Opinion|Videos|March 29, 2024
Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches
Author(s)Rebecca A. Shatsky, MD
A medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.
Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
3
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
4
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
5